Dyrskjøt, Lars http://orcid.org/0000-0001-7061-9851
Hansel, Donna E.
Efstathiou, Jason A. http://orcid.org/0000-0003-0996-0350
Knowles, Margaret A. http://orcid.org/0000-0002-9363-8657
Galsky, Matthew D. http://orcid.org/0000-0001-7655-9378
Teoh, Jeremy http://orcid.org/0000-0002-9361-2342
Theodorescu, Dan http://orcid.org/0000-0002-8708-8206
Article History
Accepted: 20 September 2023
First Online: 26 October 2023
Competing interests
: L.D. has sponsored research agreements with Natera, C2i Genomics, AstraZeneca, Photocure and Ferring, has an advisory/consulting role at Ferring, MSD and UroGen, has received speaker honoraria from AstraZeneca, Pfizer and Roche, and is a board member for BioXpedia. D.E.H. is an advisory board member for AstraZeneca. M.D.G. receives or has received research funding from Bristol Myers Squibb, Novartis, Dendreon, AstraZeneca, Merck and Genentech. M.D.G. is or was a consultant for Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Pfizer, EMD Serono, SeaGen, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, Rappta Therapeutics, Alligator, Silverback, Fujifilm, Curis, Gilead, Bicycle, Asieris, Abbvie, Analogue Devices and Veracyte. J.A.E. is or was a consultant/advisory board member and receives or has received honoraria from Blue Earth Diagnostics, Boston Scientific, AstraZeneca, Lantheus, IBA, Astellas, Pfizer, Merck, Roivant Pharma, Myovant Sciences, Janssen, Bayer Healthcare, Progenics Pharmaceuticals, Genentech, Gilead, Angiodynamics and UptoDate. The other authors declare no competing interests.